Literature DB >> 1634062

Surveillance in the routine management of ulcerative colitis: the predictive value of low-grade dysplasia.

A J Woolrich1, M D DaSilva, B I Korelitz.   

Abstract

Biopsies obtained at colonoscopy from 121 patients with ulcerative colitis (UC) for greater than 7 years were reviewed. Dysplasia or neoplasia was found in 27 patients (22%) after a mean of 16 years; 22 (18%) had dysplasia (all low grade), 2 had polyps, and 3 had carcinoma without prior dysplasia. Seven had dysplasia (or neoplasia) on the next examination, and another 4 after multiple negative examinations. Dysplasia preceded carcinoma in 4 (18%) of the 22 patients, and carcinoma occurred in 7 (6%) of 121 patients. The average time from the first encounter of dysplasia to the finding of carcinoma was 6.3 years, and 3 of 4 patients with negative second colonoscopies then had unremarkable examinations for 2-5 years. Dysplasia without cancer was found later in another 3. Dysplasia was found in 12 of 13 colectomy specimens, including the 3 from patients with cancer in whom no dysplasia had been found at surveillance colonoscopy. Active disease did not eliminate the capability to detect dysplasia or negate the value of surveillance for cancer when colonoscopy was conducted for routine clinical indications. Most dysplasia was detected in the rectum and sigmoid, supporting the value of interim sigmoidoscopies and biopsies during routine management of UC. Compliance for surveillance was diminished when the patient was asymptomatic, thereby increasing the risk of cancer. Low-grade dysplasia, like high-grade dysplasia, is predictive of future carcinoma and warrants careful follow-up. A "negative" second examination is no basis for a sense of security or relaxation of vigilance.

Entities:  

Mesh:

Year:  1992        PMID: 1634062     DOI: 10.1016/0016-5085(92)90831-i

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  26 in total

Review 1.  Cancer surveillance in inflammatory bowel disease.

Authors:  C N Bernstein
Journal:  Curr Gastroenterol Rep       Date:  1999-12

2.  Ten year follow up of ulcerative colitis patients with and without low grade dysplasia.

Authors:  C H Lim; M F Dixon; A Vail; D Forman; D A F Lynch; A T R Axon
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

3.  Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease.

Authors:  J A Eaden; J F Mayberry
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

Review 4.  The management of dysplasia associated with ulcerative colitis: colectomy versus continued surveillance.

Authors:  Martin S Friedlich; Maha Guindi; Hartley S Stern
Journal:  Can J Surg       Date:  2004-06       Impact factor: 2.089

5.  Anal transition zone in the surgical management of ulcerative colitis.

Authors:  Jennifer Holder-Murray; Alessandro Fichera
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

Review 6.  How do we assess the value of surveillance techniques in ulcerative colitis?

Authors:  C N Bernstein
Journal:  J Gastrointest Surg       Date:  1998 Jul-Aug       Impact factor: 3.452

Review 7.  Biology of colorectal cancer in ulcerative colitis.

Authors:  B A Lashner; B D Shapiro
Journal:  J Gastrointest Surg       Date:  1998 Jul-Aug       Impact factor: 3.452

Review 8.  Cancer in inflammatory bowel disease.

Authors:  Jianlin Xie; Steven H Itzkowitz
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

Review 9.  Failure of colonoscopic surveillance in ulcerative colitis.

Authors:  D A Lynch; A J Lobo; G M Sobala; M F Dixon; A T Axon
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

10.  Colorectal carcinoma in patients with ulcerative colitis and recent colonoscopy.

Authors:  S M Catnach; K R Rutter; R L Bown
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.